EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Evolving Landscape of Systemic Therapy for Liposarcoma

Hee Kyung Kim, Akshat Sarkari, Warren A Chow iD

Cancers · 22.05.2026 · 18 (11) · 1694

DOI: 10.3390/cancers18111694 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 22.05.2026. Verfasst von Hee Kyung Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Chao Family Comprehensive Cancer Center, University of California, Orange, CA 92868, USA. Die Arbeit nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Liposarcoma represents a heterogeneous group of mesenchymal malignancies with distinct molecular profiles and clinical behaviors. While localized disease is managed with surgical resection, advanced or metastatic liposarcoma poses a significant therapeutic challenge due to limited response to traditional cytotoxic chemotherapy. This review summarizes current evidence-based systemic therapies and highlights recent advances in subtype-driven treatment strategies.

Methods

We review key clinical trials supporting the use of anthracycline regimens, trabectedin, eribulin, and nuclear export inhibition with selinexor, as well as emerging targeted approaches directed at MDM2 and CDK4 amplification. In addition, we discuss the evolving role of immunotherapy, including checkpoint inhibitors and engineered T-cell receptor therapies targeting cancer–testis antigens.

Results

Integrating molecular biology with therapeutic development, we emphasize the importance of histologic and genomic classification in guiding treatment selection and clinical trial design.

Conclusion

Continued progress in biomarker-driven strategies and rational combination therapies is expected to further refine personalized treatment approaches and improve outcomes for patients with advanced liposarcoma.

Schlagwörter

Stichwörter der Autor:innen

CDK4 inhibitionMDM2 amplificationT-cell receptor therapyXPO1 inhibitorliposarcomasystemic therapytargeted therapy

Autor:innen und Institutionen

  • Chao Family Comprehensive Cancer Center, University of California, Orange, CA 92868, USA.
  • Division of Hematology/Oncology, Department of Medicine, University of California, Orange, CA 92868, USA.
  • Department of Internal Medicine, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea.

ORCID-Profile: Warren A Chow

Zitieren

APA

Kim, H. K., Sarkari, A., & Chow, W. A. (2026). The Evolving Landscape of Systemic Therapy for Liposarcoma. Cancers, 18(11), 1694. https://doi.org/10.3390/cancers18111694

Vancouver

Kim HK, Sarkari A, Chow WA. The Evolving Landscape of Systemic Therapy for Liposarcoma. Cancers. 2026;18(11):1694. doi:10.3390/cancers18111694

BibTeX
@article{Kim2026,
  author = {Kim, Hee Kyung and Sarkari, Akshat and Chow, Warren A},
  title = {The Evolving Landscape of Systemic Therapy for Liposarcoma},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1694},
  doi = {10.3390/cancers18111694}
}
Kostenlos starten →